Off-label use of rituximab in dermatology: pemphigus treatment

Anais Brasileiros de Dermatologia

Lislaine Bomm¹  Tainá Scalfoni Fracaroli¹  João Luz Sodré¹  Aline Bressan¹  Alexandre Carlos Gripp¹ 

关键词: biological treatment;    immunosuppressive agents;    pemphigus;    Imunossupressores;    Pênfigo;    Tratamento biológico;   

DOI  :  10.1590/abd1806-4841.20131905

来源: SciELO

【 摘 要 】

Since its approval in 1997 by the FDA (United States Food and Drug Administration), rituximab has been used for certain B-cell lymphomas and treatment-resistant rheumatoid arthritis. Nevertheless, over the past 14 years, many case reports have demonstrated the efficacy of off-label rituximab in several dermatological inflammatory conditions. This study describes two cases of pemphigus vulgaris and two cases of pemphigus foliaceous that were treated with rituximab at 375 mg/m2 once a week for 4 weeks, and that responded well to treatment.

【 授权许可】

CC BY-NC   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License